Over $1 in June or moreThe Company is finalizing production supply agreements with key Bangladesh pharmaceutical partners to produce its Ivectosol™ 1% for use and distribution throughout Bangladesh and as a production hub for broader global distribution. The production scheduling and pricing are currently being finalized under non-disclosure agreement (“NDA”), including securing the sufficient Ivermectin Active Pharmaceutical Ingredient (“API”) quantity for anticipated global demand.